IAVI, a nonprofit organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases, has recently signed a lease for 29,782 square feet of space at 95 Greene Street in Jersey City. This move will relocate their Vaccine Design and Development Lab (DDL) from the Brooklyn Army Terminal to a state-of-the-art life sciences building spanning over 350,000 square feet.
The regional representation for IAVI is being handled by CBRE’s team of John Isaacs, Joseph DeRosa Jr., Conor Dolan and others. According to Christopher L. Parks Ph.D., Associate Vice President of Viral Vaccines and Head of the IAVI DDL: “This upgraded lab space is specifically designed to meet our unique infrastructure needs as leaders in vaccine research & development within the global health community.” The new location in Jersey City will allow IAVI to strengthen connections with partners across New York & New Jersey’s thriving life sciences industries.
The DDL serves as an essential hub for vaccine R&D at IAVI – playing an integral role in their efforts towards developing vaccines against Ebola virus disease (EVD), Marburg virus disease (MVD), Lassa fever (LF) as well as COVID-19. Formerly known as the International AIDS Vaccine Initiative – this nonprofit aims at translating scientific breakthroughs into accessible solutions that can improve global health outcomes.
This news was first reported on Connect CRE , your source for all things commercial real estate without mentioning any specific locations or organizations such as “Connect” or “Connect LA” or “Connect Texas”.
